Idorsia: Failure in Phase III - European Biotechnology
Ein schweres Erbe für Jean-Paul Clozel | NZZ
Jean-Paul Clozel | EY - Global
Ernst and Young's world Entrepreneur Dr Jean Paul Clozel | Flickr
Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) and Actelion CEO and founder Jean-Paul Clozel attend a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann
Jean-Paul Clozel: «Idorsia steht nicht zum Verkauf» | Unternehmen Gesundheit | Finanz und Wirtschaft
PharmaBoardroom - Jean-Paul Clozel - CEO & Co-Founder, Actelion, Switzerland
Idorsia's rival to Merck's insomnia drug clears phase 3 test | FierceBiotech
Jean-Paul Clozel, co-founder of Actelion Ltd., speaks during a news... News Photo - Getty Images
PharmaBoardroom - Jean-Paul Clozel - CEO & Co-Founder, Actelion, Switzerland
Jean-Paul Clozel - Crunchbase Person Profile
Johnson & Johnson Vice President and Worldwide Chairman Pharmaceuticals Joaquin Duato (L-R), Actelion CEO and founder Jean-Paul Clozel and Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels pose for photographers at
Molecular Millionaire: Jean-Paul Clozel of Actelion | by Dr. Clemen Chiang | Spiking
Actelion Could Boost Takeover Price for Johnson & Johnson
Swiss biotech Actelion CEO Jean-Paul Clozel endorses independence not acquisition - CEOWORLD magazine
Startup Guide - Jean-Paul and Martine Clozel are... | Facebook